Next Article in Journal
Functional Prediction of Candidate MicroRNAs for CRC Management Using in Silico Approach
Previous Article in Journal
Impact of High Salt Diet on Cerebral Vascular Function and Stroke in Tff3−/−/C57BL/6N Knockout and WT (C57BL/6N) Control Mice
Previous Article in Special Issue
Zebrafish and Medaka: Two Teleost Models of T-Cell and Thymic Development
Open AccessArticle

Pharmacological Enhancement of Regeneration-Dependent Regulatory T Cell Recruitment in Zebrafish

1
Diabetes and Metabolism Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
2
Developmental and Stem Cell Biology Division, Victor Chang Cardiac Research Institute, Darlinghurst, NSW 2010, Australia
3
St Vincent’s Clinical School, University of New South Wales, Kensington, NSW 2052, Australia
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(20), 5189; https://doi.org/10.3390/ijms20205189
Received: 27 September 2019 / Revised: 14 October 2019 / Accepted: 15 October 2019 / Published: 19 October 2019
(This article belongs to the Special Issue Zebrafish Models of Lymphocyte Development and Lymphocytic Cancers)
Regenerative capacity varies greatly between species. Mammals are limited in their ability to regenerate damaged cells, tissues and organs compared to organisms with robust regenerative responses, such as zebrafish. The regeneration of zebrafish tissues including the heart, spinal cord and retina requires foxp3a+ zebrafish regulatory T cells (zTregs). However, it remains unclear whether the muted regenerative responses in mammals are due to impaired recruitment and/or function of homologous mammalian regulatory T cell (Treg) populations. Here, we explore the possibility of enhancing zTreg recruitment with pharmacological interventions using the well-characterized zebrafish tail amputation model to establish a high-throughput screening platform. Injury-infiltrating zTregs were transgenically labelled to enable rapid quantification in live animals. We screened the NIH Clinical Collection (727 small molecules) for modulators of zTreg recruitment to the regenerating tissue at three days post-injury. We discovered that the dopamine agonist pramipexole, a drug currently approved for treating Parkinson’s Disease, specifically enhanced zTreg recruitment after injury. The dopamine antagonist SCH-23390 blocked pramipexole activity, suggesting that peripheral dopaminergic signaling may regulate zTreg recruitment. Similar pharmacological approaches for enhancing mammalian Treg recruitment may be an important step in developing novel strategies for tissue regeneration in humans. View Full-Text
Keywords: regulatory T cell; zebrafish; small molecule screen; pramipexole; dopamine signaling regulatory T cell; zebrafish; small molecule screen; pramipexole; dopamine signaling
Show Figures

Figure 1

MDPI and ACS Style

Zwi, S.F.; Choron, C.; Zheng, D.; Nguyen, D.; Zhang, Y.; Roshal, C.; Kikuchi, K.; Hesselson, D. Pharmacological Enhancement of Regeneration-Dependent Regulatory T Cell Recruitment in Zebrafish. Int. J. Mol. Sci. 2019, 20, 5189.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop